Interleukin-6 and melanoma

Melanoma Research

Volumn 22, Issue 5, 2012, Pages 327-333

  Hoejberg, Lise ^a,b   Bastholt, Lars ^a   Schmidt, Henrik ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biomarker; interleukin 6; melanoma

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN 130; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 1; LACTATE DEHYDROGENASE; STAT3 PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIGAND BINDING; LYMPH NODE METASTASIS; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; ULTRAVIOLET RADIATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MELANOMA; MICE; MICE, TRANSGENIC; PROGNOSIS;

EID: 84866257347     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283543d72     Document Type: Review

References (76)

1. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-1710. (Pubitemid 19251549)
2. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52:2784-2789. (Pubitemid 37339708)
3. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61:575-584.
4. Wallenius V,Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8:75-79. (Pubitemid 34101732)
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71-78. (Pubitemid 38082155)
6. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27:3330-3337.
7. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-759. (Pubitemid 41400849)
8. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248:171-183. (Pubitemid 33702479)
9. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37. (Pubitemid 43053650)
10. Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol 1982; 128:1296-1301. (Pubitemid 12188454)
11. Yoshizaki K, Nakagawa T, Fukunaga K, Tseng LT, Yamamura Y, Kishimoto T. Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol 1984; 132:2948-2954. (Pubitemid 14105681)
12. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-76. (Pubitemid 16008419)
13. Sehgal PB, Walther Z, Tamm I. Rapid enhancement of beta 2-interferon/B-cell differentiation factor BSF-2 gene expression in human fibroblasts by diacylglycerols and the calcium ionophore A23187. Proc Natl Acad Sci USA 1987; 84:3663-3667. (Pubitemid 17088341)
14. Zilberstein A, Ruggieri R, Korn JH, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986; 5:2529-2537.
15. Van DJ, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987; 165:914-919. (Pubitemid 17059462)
16. Andus T, Geiger T, Hirano T, Northoff H, Ganter U, Bauer J, et al. Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett 1987; 221:18-22. (Pubitemid 17124045)
17. Wolvekamp MC, Marquet RL. Interleukin-6: historical background, genetics and biological significance. Immunol Lett 1990; 24:1-9. (Pubitemid 20123586)
18. Kishimoto T. The biology of interleukin-6. Blood 1989; 74:1-10. (Pubitemid 19187402)
19. Lotz M. Interleukin-6: a comprehensive review. Cancer Treat Res 1995; 80:209-233.
20. Lukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 2007; 117 (5-6):247-251. (Pubitemid 47515189)
21. Song M, Kellum JA. Interleukin-6. Crit Care Med 2005; 33 (Suppl): S463-S465. (Pubitemid 41785989)
22. Van SJ. Interleukin-6: an overview. Annu Rev Immunol 1990; 8:253-278.
23. Assier E, Boissier MC, Dayer JM. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010; 77:532-536.
24. Huang SP,Wu MS, Shun CT,Wang HP, Lin MT, Kuo ML, et al. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 2004; 11:517-527.
25. Biro L, Domjan G, Falus A, Jakab L, Cseh K, Kalabay L, et al. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 1998; 28:679-686. (Pubitemid 28380366)
26. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242:237-239. (Pubitemid 19020112)
27. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84:7251-7255.
28. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1:245-251. (Pubitemid 128539449)
29. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003; 11:60-62. (Pubitemid 36722854)
30. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005; 8:265-269. (Pubitemid 40586184)
31. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 2007; 110:1911-1928. (Pubitemid 350036849)
32. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52:232-234. (Pubitemid 23094315)
33. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993; 13:45-51. (Pubitemid 23247813)
34. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005; 12:131-140. (Pubitemid 40868672)
35. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008; 13:59-78.
36. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2010; 90:484-494.
37. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63:1149-1157. (Pubitemid 120035064)
38. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502-2512. (Pubitemid 41540626)
39. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14:109-119.
40. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268:160-167. (Pubitemid 32052260)
41. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006; 1091:151-169. (Pubitemid 47092233)
42. Berek JS, Chung C, Kaldi K,Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991; 164:1038-1042.
43. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52:3317-3322.
44. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77:2794-2795.
45. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 1995; 13:575-582.
46. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005; 15:199-204. (Pubitemid 40839468)
47. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45:542-549.
48. Salgado R, Junius S, Benoy I, Van DP, Vermeulen P, Van ME, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103:642-646. (Pubitemid 36091468)
49. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999; 18:1023-1032. (Pubitemid 29086279)
50. Fontaine V, Mahieu M, Content J. Interferon-gamma and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways. Melanoma Res 1998; 8:24-30. (Pubitemid 28114298)
51. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96:180-185.
52. Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992; 89:9215-9219.
53. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120:1281-1288. (Pubitemid 23064182)
54. Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res 1995; 55:2200-2205.
55. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999; 84:160-168. (Pubitemid 29133828)
56. Eberlein-Konig B, Jager C, Przybilla B. Ultraviolet B radiation-induced production of interleukin 1alpha and interleukin 6 in a human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agents. Br J Dermatol 1998; 139: 415-421. (Pubitemid 28430457)
57. Urbanski A, Schwarz T, Neuner P, Krutmann J, Kirnbauer R, Kock A, et al. Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol 1990; 94:808-811. (Pubitemid 20184383)
58. von FV, Cordoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, et al. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005; 166:831-841. (Pubitemid 40315640)
59. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 2006; 42:559-576. (Pubitemid 44595080)
60. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008; 67:1516-1523.
61. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009; 69:88-96.
62. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Longterm safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008; 68:1580-1584.
63. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86:685-691.
64. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, et al. Antiinterleukin-receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007; 46:771-774. (Pubitemid 46902277)
65. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69: 911-913. (Pubitemid 24140673)
66. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14:1697-1703. (Pubitemid 26134229)
67. Vuoristo MS, Kellokumpu-Lehtinen P, Laine S, Parvinen LM, Hahka-Kemppinen M, Korpela M, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res 2000; 10:237-241.
68. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7:151-156. (Pubitemid 37531603)
69. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 2005; 22: 241-246. (Pubitemid 41176320)
70. Deichmann M, Benner A, Waldmann V, Bock M, Jackel A, Naher H. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res 2000; 19:301-307.
71. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C,Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 1996; 2: 1405-1409. (Pubitemid 26299441)
72. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999; 9:181-188. (Pubitemid 29331527)
73. Mouawad R, Soubrane C, Rixe O, Khayat D, Spano JP. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res 2006; 16:335-340. (Pubitemid 44090177)
74. Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, Schmidt H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 2012; 22:287-293.
75. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM Velikokhatnaya L,Winans MT, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-{alpha}2b. Clin Cancer Res 2007; 13:2422-2428. (Pubitemid 46698593)
76. Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, et al. Relationship between responsiveness of cancer cells to oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumourinfiltrating lymphocytes. J Pathol 2008; 216:451-459.